Showing results (1-10 of 402) with videos related to
Sort By:
Pageof 41
Clinical Orthopaedics and Related Research|November 6, 2003
Biochemical markers and skeletal metastasesLaurence M Demers, Luis Costa, Allan LiptonJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases statusLuis Costa, Laurence M Demers, A Gouveia-Oliveira, et al.Breast Disease|December 7, 2011
Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates?Allan Lipton, Luis Costa, Robert E ColemanSupportive Cancer Therapy|July 18, 2008
Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastasesLuis Costa, Allan Lipton, Robert E ColemanCritical Reviews in Oncology/Hematology|March 1, 2011
Anticancer evidence for zoledronic acid across the cancer continuumLuis Costa, Peter Harper, Robert E Coleman, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 9, 2008
Impact of skeletal complications on patients' quality of life, mobility, and functional independenceLuis Costa, Xavier Badia, Edward Chow, et al.International Journal of Clinical Oncology|May 11, 2012
Treatment of bone metastases before the onset of painLuis Costa, Allan Lipton, Peyman Hadji, et al.Breast Cancer Research and Treatment|June 25, 2010
Prognostic factors for skeletal complications from metastatic bone disease in breast cancerJanet E Brown, Richard J Cook, Allan Lipton, et al.American Journal of Clinical Oncology|August 5, 2009
Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastasesAllan Lipton, Cynthia Campbell-Baird, Harold Harvey, et al.Cancer|January 28, 2003
Bone markers in the management of patients with skeletal metastasesLaurence M DemersPageof 41